Protocol Ledger

NCT04443881 · Phase II/III · COMPLETED

Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

Interventional Phase II/III clinical trial protocol NCT04443881 sponsored by Fundacion Miguel Servet in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-08 Enrollment: 179 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04443881
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)179 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04443881
Protocol FieldVerified Registry Value
NCT IdentifierNCT04443881
Consolidated Lead SponsorFundacion Miguel Servet
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment179 participants (ACTUAL)
Registered Start Date2020-05-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04443881
Hospital Research SiteLocationSite Profile
Hospital Universitario Miguel ServetZaragoza, SpainOpen Hospital Dossier ->
Hospital Universitario Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Complejo Hospitalario de NavarraPamplona, SpainOpen Hospital Dossier ->
Hospital Universitario La PazMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI